Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Following the results of the phase III CLEOPATRA and EMELIA trials, a consensus has emerged regarding the optimal systemic treatment sequence for HER2-positive metastatic breast cancer (mBC). Although there has been a surge of novel treatment options in the United States (U.S.) for HER2-positive mBC over the past 20 years, there is also concern regarding increasing drug prices and the ability of public and private payers to reasonably keep up.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.